Xin Lang Cai Jing·2025-10-29 07:41Core Viewpoint - Junshi Biosciences (1877.HK) has experienced a significant decline in stock price, dropping 35.2% from its peak earlier this year, despite reporting a year-on-year revenue increase of 31.4% for Q3 2025 [1] Financial Performance - For Q3 2025, the company reported revenue of approximately 637.5 million RMB, representing a year-on-year increase of 31.4% [1] - The net loss for the same period was approximately 183 million RMB, with a basic earnings per share of -0.18 RMB [1] - For the first three quarters of 2025, total revenue reached about 1.8 billion RMB, marking a year-on-year increase of 42.06% [1] - The net loss for the first three quarters was approximately 596 million RMB [1] - The cash flow from operating activities for the first three quarters was negative, amounting to approximately -343 million RMB [1]